IQVIA Laboratories is a company that provides integrated lab services covering from the early stages of drug discovery to the clinical phase. For non-clinical studies, in addition to conducting tests in-house, they have a system in place to support the entire development process by handling everything from custom model development to analysis. This section introduces the features of IQVIA Laboratories' non-clinical studies.
One of the significant strengths of IQVIA Laboratories' preclinical testing services is its flexible study design capabilities, centered around the development of custom in vivo models. Rather than relying on existing standard models,Design and construct appropriate disease models according to the target disease, mechanism of action, and endpoints to be evaluated.We have established a system to support research. We cover a wide range of fields, including infectious diseases, tumors, and immune disorders, and can modify models and optimize conditions according to research objectives. Furthermore, specialists in immunology and molecular biology are involved from the study design stage to construct an integrated evaluation system that combines in vivo studies with various bioassays. We achieve the generation of highly reproducible and practical data, with a view to bridging from early drug discovery to clinical application.
By combining high-throughput ADME (Absorption, Distribution, Metabolism, Excretion) testing with advanced bioanalysis, we improve development efficiency in the preclinical stage. Leveraging automated testing platforms,Rapid and parallel evaluation of numerous compoundsThis allows for the early screening of promising candidates. By comprehensively analyzing metabolite identification, drug-drug interactions, and biomarker measurements, drug properties can be understood from multiple angles. A system is in place to reduce risks after clinical transition and expedite decision-making, thereby supporting the overall efficiency of the drug discovery process.
We have established lab operations that comply with GLP (Good Laboratory Practice) and a testing system that meets international standards.We can provide high-quality data with regulatory submission in mind.All types of studies, including bioanalysis, are conducted under standardized procedures to ensure data reliability and reproducibility. Furthermore, our animal testing facilities are operated in consideration of international guidelines, meeting the standards required for global development. By leveraging our global network of facilities, we can design studies and build data packages that comply with regional regulatory requirements. We support efficient project advancement for international joint development and country-specific applications.
LCMV models areRepresentative in vivo models for evaluating immune responses to viral infectionsIQVIA Laboratories utilizes it as a challenge study in a BSL-2 environment, serving to evaluate the efficacy of vaccines and immunotherapies. A key feature is its ability to analyze both cellular immunity (T-cell response) and humoral immunity. It is positioned as a foundational model for preclinical evaluation in the infectious disease field.
Oncogenic proliferation modelsAn in vivo model for evaluating the efficacy of anticancer drugs and immune checkpoint inhibitorsAt IQVIA Laboratories, treatment efficacy is verified using indicators such as tumor growth inhibition and changes in immune response. This is particularly utilized in the field of immuno-oncology for analyzing drug mechanisms of action and exploring combination therapies. It plays a crucial role in evaluating efficacy during the preclinical stage.
Information on non-clinical study examples was not available on the official website.
| Address | IQVIA Laboratories Japan K.K.: 2-5-10 Aomi, Koto-ku, Tokyo, Telecom Center Building |
|---|---|
| Tel | 03-6859-9620 |
| Website | https://www.iqvia.com/ja-jp/locations/japan |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.